Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 402Rectal Neoplasms 151Colonic Neoplasms 148Pancreatic Neoplasms 113Stomach Neoplasms 106Neoplasm Metastasis 88Neoplasms 74Esophageal Neoplasms 59Small Cell Lung Carcinoma 44Neuroblastoma 42Lung Neoplasms 42Glioblastoma 38Carcinoma, Non-Small-Cell Lung 37Esophageal Squamous Cell Carcinoma 33Brain Neoplasms 33Unspecified Adult Solid Tumor, Protocol Specific 31Glioma 31Breast Neoplasms 28Central Nervous System Neoplasms 27Adenocarcinoma Of Esophagus 27Sarcoma 26Gliosarcoma 22Astrocytoma 22Rhabdomyosarcoma 21Sarcoma, Ewing 18Adenocarcinoma 18Gastrointestinal Neoplasms 17Oligodendroglioma 16Cholangiocarcinoma 14Recurrence 13

Interventions

Ifosfamide 5Filgrastim 5Doxorubicin 5Gemcitabine 4Docetaxel 4Radiotherapy 3Proton Therapy 3Carboplatin 3regorafenib 2ivosidenib 2enasidenib 2belinostat 2Sunitinib 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immune Checkpoint Inhibitors 2HhAntag691 2Fluorouracil 2Etoposide 2Epirubicin 2Cyclophosphamide 2Cisplatin 2Chemotherapy, Adjuvant 2Celecoxib 2Bevacizumab 2venetoclax 1toripalimab 1temsirolimus 1tanespimycin 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chondrosarcoma × Irinotecan × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡